These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 17088473)

  • 1. Glycoprotein IIb/IIIa inhibitors in the elderly: fear of age or age of fear?
    Montalescot G
    Circulation; 2006 Nov; 114(19):2004-6. PubMed ID: 17088473
    [No Abstract]   [Full Text] [Related]  

  • 2. Oral glycoprotein IIb/IIIa receptor inhibitors in patients with cardiovascular disease: why were the results so unfavourable.
    Leebeek FW; Boersma E; Cannon CP; van de Werf FJ; Simoons ML
    Eur Heart J; 2002 Mar; 23(6):444-57. PubMed ID: 11863347
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of GPIIb/IIIa inhibitors in cardiovascular medicine.
    Ahrens I; Peter K; Bode C
    Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):233-42. PubMed ID: 15030283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platelet glycoprotein IIb/IIIa receptor inhibitors: is their future as bright as their past?
    Leesar MA
    Catheter Cardiovasc Interv; 2008 Jun; 71(7):907-8. PubMed ID: 18498141
    [No Abstract]   [Full Text] [Related]  

  • 5. The emerging role of platelet glycoprotein IIb/IIIa inhibitors in managing high-risk patients with non-ST segment elevation acute coronary syndromes.
    Bolognese L
    Curr Med Res Opin; 2007 Jun; 23(6):1217-26. PubMed ID: 17559721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Reflections on GPIIb/IIIA inhibitors ... and all around ...].
    Neri Serneri GG
    G Ital Cardiol; 1999 Apr; 29(4):467-71. PubMed ID: 10327329
    [No Abstract]   [Full Text] [Related]  

  • 7. [Anti-platelet treatment in cardiology].
    De Benedetti E
    Rev Med Suisse; 2005 Mar; 1(9):619-22. PubMed ID: 15813338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific glycoprotein IIb/IIIa antagonists and inflammation.
    Ercan E
    Int J Cardiol; 2004 Mar; 94(1):121-2. PubMed ID: 14996486
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial.
    Jolly SS; Faxon DP; Fox KA; Afzal R; Boden WE; Widimsky P; Steg PG; Valentin V; Budaj A; Granger CB; Joyner CD; Chrolavicius S; Yusuf S; Mehta SR
    J Am Coll Cardiol; 2009 Jul; 54(5):468-76. PubMed ID: 19628124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GP IIb/IIIa blockade during peripheral artery interventions.
    Tepe G; Wiskirchen J; Pereira P; Claussen CD; Miller S; Duda SH
    Cardiovasc Intervent Radiol; 2008; 31(1):8-13. PubMed ID: 17479207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
    Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
    Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions].
    Fettser DV; Preobrazhenskiĭ DV; Batyraliev TA; Sidorenko BA; Aĭtach V
    Ter Arkh; 2009; 81(1):84-7. PubMed ID: 19253720
    [No Abstract]   [Full Text] [Related]  

  • 13. Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment.
    Mathewkutty S; McGuire DK
    Expert Rev Cardiovasc Ther; 2009 May; 7(5):541-9. PubMed ID: 19419262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of upstream antiplatelet therapy use before primary percutaneous coronary intervention for acute ST-elevation myocardial infarction (from the CRUSADE National Quality Improvement Initiative).
    Alexander D; Mann N; Ou FS; Peterson ED; Ohman EM; Gibler WB; Roe MT
    Am J Cardiol; 2008 Nov; 102(10):1335-40. PubMed ID: 18993151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Various therapy options. Medical Chemistry of platelet aggregation inhibitors].
    Zettl H; Schubert-Zsilavecz M
    Pharm Unserer Zeit; 2009; 38(4):314-9. PubMed ID: 19572349
    [No Abstract]   [Full Text] [Related]  

  • 16. Into the future with glycoprotein IIb/IIIa receptor antagonists.
    White N
    Drugs R D; 1999 May; 1(5):393-5. PubMed ID: 10566074
    [No Abstract]   [Full Text] [Related]  

  • 17. The biology of glycoprotein IIb-IIIa.
    Plow EF; Byzova T
    Coron Artery Dis; 1999 Dec; 10(8):547-51. PubMed ID: 10599532
    [No Abstract]   [Full Text] [Related]  

  • 18. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
    O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
    J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents?
    Tricoci P; Newby LK
    Cardiol Rev; 2008; 16(2):89-94. PubMed ID: 18281911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycoprotein IIb-IIIa inhibitors in the emergency department for patients with non-ST-elevation acute coronary syndromes: principles and practices.
    Lefebvre CW; Hoekstra JW; Bonaca M; Giugliano R
    J Emerg Med; 2009 Feb; 36(2):162-70. PubMed ID: 18353601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.